GMDP for psoriasis.
Williamson
D
D
Chawla
M
M
Marks
R
R
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000284:Administration, Oral; D005500:Follow-Up Studies; D006801:Humans; D010146:Pain / Q000209:etiology; D011537:Pruritus / Q000628:therapy; D011565:Psoriasis / Q000145:classification / Q000473:pathology / Q000628:therapy*; D012720:Severity of Illness Index; D016176:T-Lymphocyte Subsets / Q000473:pathology; D014839:Vomiting / Q000209:etiology
D000276:Adjuvants, Immunologic; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C063429:glucosaminylmuramyl-2-alanine-D-isoglutamine